NEW YORK (GenomeWeb News) – Response Genetics has signed a deal with Roche Diagnostics to support the development of a cancer assay.
The Los Angeles-based firm said today that it had licensed to Roche non-exclusive rights to use its PCR analysis technology to assess human epidermal growth factor type 2 gene expression. A test that can accurately measure HER2 expression could assist physicians with treatment decisions for patients with certain cancers in tissues such as breast.
"This agreement strengthens our long relationship with Roche and fulfills a promise we made during our initial public offering to license our intellectual property while protecting our intellectual capital freedom," Kathleen Danenberg, Response Genetics' president and CEO, said in a statement.
Financial and other terms of the license were not disclosed.